SCHEMBL5859014

SCHEMBL5859014

COC(=O)c1cccc(Cc2c(C)c(OC)c(OC)c(OC)c2OC)c1OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 3/20 0.41
TSHR P16473 2/20 0.41
USP2 O75604 1/20 0.41
HSD17B10 Q99714 1/20 0.41
BCHE P06276 2/20 0.40
PTGER1 P34995 2/20 0.40
HIF1A Q16665 2/20 0.40
MAPT P10636 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5859876 0.91 PTGER1 (0.46) LMNAHPGDNPC1RAB9AMEN1
SCHEMBL27581527 0.81 SLC6A3 (0.43) LMNAMEN1KMT2AALDH1A1TSHR
SCHEMBL5859425 0.80 ALDH1A1 (0.40) LMNAHPGDKMT2AALDH1A1TSHR
SCHEMBL5859062 0.80 BCHE (0.42) HPGDALDH1A1BCHEPTGER1MAPT
SCHEMBL27581191 0.80 MAPT (0.47) LMNAHPGDRAB9AALDH1A1PTGER1
SCHEMBL27581102 0.79 ALDH1A1 (0.46) LMNAHPGDNPC1RAB9AMEN1
SCHEMBL5859832 0.79 FFAR4 (0.47) LMNAHPGDNPC1RAB9AALDH1A1
SCHEMBL5859909 0.79 FOLH1 (0.46) LMNAHPGDRAB9AALDH1A1MAPT
SCHEMBL3511761 0.79 LMNA (0.63) LMNAHPGDNPC1RAB9AKMT2A
SCHEMBL6095629 0.79 FOLH1 (0.55) MEN1KMT2APTGER1MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7122543-B2 Substituted benzoic acid derivatives having NF-κB inhibiting action DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-10-17 US disclosed
EP-1437339-A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-KAPPA B INHIBITING ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-07-14 EP disclosed
US-20040039061-A1 Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039061-A1 Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity NFKBIA, NFKB2, IKBKB LMNA 869/4885HPGD 1270/4885NPC1 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.